|Bid||7.27 x N/A|
|Ask||7.27 x N/A|
|Day's Range||7.25 - 7.25|
|52 Week Range||6.06 - 13.17|
|Beta (5Y Monthly)||1.17|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 02, 2023 - May 08, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||56.67|
Subscribe to Yahoo Finance Plus to view Fair Value for 1HM.F
Following the decision to discontinue the development of pipeline candidates, Bellicum Pharmaceuticals (BLCM) is left with no candidate in clinical development. The stock is down 50% post the news.
Neoleukin (NLTX) seeks strategic options to maximize shareholder's value. This includes the undertaking of another restructuring plan to reduce 70% of the existing workforce.
Data from late-stage label expansion studies show that AstraZeneca's (AZN) cancer drugs are effective for treating non-small cell lung cancer indications.